Pasireotide

Somatostatin Analog — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

Key facts

Pasireotide is an onp drug in the Somatostatin Analog class catalogued in DrugCentral. It was first approved by the FDA in 2012. Its mechanism of action is classified as Somatostatin Receptor Agonists. DrugCentral lists 5 molecular targets, including SSTR5, Sstr2 and SSTR2. Recorded indications include Hypercortisolism.

• Approval status: onp (first approved 2012 by the FDA).
• Drug class: Somatostatin Analog.
• Mechanism of action: Somatostatin Receptor Agonists.
• Molecular targets: SSTR5, Sstr2, SSTR2 and SSTR3 (5 listed in DrugCentral).
• Indications: Hypercortisolism.
• ATC code: H01CB05 (Somatostatin and analogues).
• Molecular formula: C58H66N10O9; molecular weight 1047.23 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Hypercortisolism

Mechanism & targets

• Mechanism of action (MoA): Somatostatin Receptor Agonists
• Established pharmacologic class: Somatostatin Analog

Molecular targets (5)

Target	Gene	Action	Activity
Somatostatin receptor type 5	SSTR5	agonist	IC50 9.80
Somatostatin receptor type 2	Sstr2	agonist	EC50 9.07
Somatostatin receptor type 2	SSTR2	agonist	IC50 9.00
Somatostatin receptor type 3	SSTR3	agonist	IC50 8.80
Somatostatin receptor type 1	SSTR1	agonist	IC50 8.00

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2012-12-14	FDA	—	NOVARTIS	Yes

ATC classification

ATC code	Therapeutic hierarchy
H01CB05	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES › HYPOTHALAMIC HORMONES › Somatostatin and analogues

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Hyperglycaemia	757.9
Diabetes mellitus	605.4
Blood glucose increased	138.1
Glycosylated haemoglobin increased	124.3
Adrenal insufficiency	119.3
Hypoglycaemia	110.7
Cholelithiasis	92.7
Diabetes mellitus inadequate control	87.9
Polyuria	82.2
Hyperadrenocorticism	80.7
Cortisol free urine increased	80.5
Insulin-like growth factor increased	73.8

Chemical structure

• Molecular formula: C₅₈H₆₆N₁₀O₉
• Molecular weight: 1047.23 g/mol
• CAS number: —
• InChIKey: VMZMNAABQBOLAK-SLLFKNDXSA-N
• PubChem CID: 9941444

NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)C(NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Pasireotide used for?

DrugCentral lists the following indications for Pasireotide: Hypercortisolism.

How does Pasireotide work?

Pasireotide is classified as Somatostatin Receptor Agonists; its molecular targets in DrugCentral include SSTR5 (agonist), Sstr2 (agonist), SSTR2 (agonist) and SSTR3 (agonist).

When was Pasireotide first approved?

Pasireotide was first approved by the FDA in 2012.

What drug class does Pasireotide belong to?

Pasireotide is in the Somatostatin Analog class.

What is the chemical formula of Pasireotide?

Pasireotide has the molecular formula C58H66N10O9 and a molecular weight of 1047.23 g/mol.

Sources

• DrugCentral drug card 4329 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3349607 — compound record and bioactivity
• PubChem CID 9941444 — chemical identifiers
• DrugBank DB06663 — drug record
• FDA UNII 98H1T17066 — substance identity
• DailyMed: FDA labels for Pasireotide — current prescribing information (label search)
• UniProt P35346 (SSTR5) — target protein
• UniProt P30874 (SSTR2) — target protein
• UniProt P32745 (SSTR3) — target protein
• UniProt P30872 (SSTR1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.